Table 3.
Indications for TKI resistance testing in patient cohort for TKD mutation
| Patients (n=90) | Percentage (%) | |
|---|---|---|
| Baseline accelerated phase | 2 | 2 |
| Baseline blast crisis | 1 | 1 |
| Progression to accelerated phase | 5 | 6 |
| Progression to blast crisis | 6 | 7 |
| Loss of complete hematologic response (CHR) | 14 | 16 |
| Cytogenetic response failure | 5 | 6 |
| Cytogenetic response failure with loss of CHR | 1 | 1 |
| Molecular response failure | 51 | 57 |
| Molecular and cytogenetic response failure | 4 | 4 |
| Molecular response failure with loss of CHR | 1 | 1 |